S&P 500
5,966.52
-0.1%
-$4.29
DJI
42,490.36
+0.1%
+$62.62
NASDAQ
19,424.00
-0.2%
-$36.49
Bitcoin
103,043.00
-2.0%
-2,142.22
AAPL
$202.40
-0.2%
-$0.42
AMZN
$209.82
+1.2%
+$2.59
GOOG
$171.52
+1.3%
+$2.13
META
$688.65
+0.1%
+$0.70
MSFT
$469.50
+1.2%
+$5.62
NVDA
$141.00
-0.7%
-$0.92
TSLA
$293.04
-11.7%
-$39.01
MiNK Therapeutics (NASDAQ: INKT)
$7.29
(2.6%)
$0.19
Price as of June 5, 2025, 2:37 p.m. ET
MiNK Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
MiNK Therapeutics Company Info
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.